RVXCF (Resverlogix) Common Stock : $334.42 Mil (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Common Stock?

Resverlogix's quarterly common stock increased from Mar. 2024 ($334.01 Mil) to Jun. 2024 ($334.18 Mil) and increased from Jun. 2024 ($334.18 Mil) to Sep. 2024 ($334.42 Mil).

Resverlogix's annual common stock increased from Dec. 2021 ($326.89 Mil) to Dec. 2022 ($331.42 Mil) and increased from Dec. 2022 ($331.42 Mil) to Dec. 2023 ($333.72 Mil).

Resverlogix Common Stock Historical Data

The historical data trend for Resverlogix's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Common Stock Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

284.91

305.64

326.89

331.42

333.72

Resverlogix Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															333.65	333.72	334.01	334.18	334.42

Resverlogix Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Resverlogix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

0VF9:UK RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.